首页   按字顺浏览 期刊浏览 卷期浏览 Deferoxamine Test and PTH Serum Levels Are Useful Not to Recognize but to Exclude Alumi...
Deferoxamine Test and PTH Serum Levels Are Useful Not to Recognize but to Exclude Aluminum-Related Bone Disease

 

作者: S. Mazzaferro,   G. Coen,   P. Ballanti,   S. Costantini,   F. Bondatti,   R. Giordano,   M. Manni,   M. Pasquali,   I. Perruzza,   D. Sardella,   E. Bonucci,  

 

期刊: Nephron  (Karger Available online 1992)
卷期: Volume 61, issue 2  

页码: 151-157

 

ISSN:1660-8151

 

年代: 1992

 

DOI:10.1159/000186863

 

出版商: S. Karger AG

 

关键词: Aluminum-related bone disease;Bone aluminum stain;Bone aluminum content;Bone histomorphometry;Deferoxamine test;Hemodialysis;Renal osteodystrophy

 

数据来源: Karger

 

摘要:

The use of noninvasive diagnostic tools, like the deferoxamine (DFO) test and serum iPTH, to identify aluminum-related bone disease has proved to be inadequate due to false-negative cases; therefore, bone biopsy becomes a necessary diagnostic procedure. Our purpose was to verify whether these non-invasive parameters, appropriately used, may result valid in the identification of patients not at risk of A1 toxicity, therefore restricting the need for histologic evaluation. We studied 68 hemodialyzed patients, aged 49.0 ± 11.6 years, with a M/F ratio of 37/31 and a dialytic age of 85.0 ± 47.0 months, by means of bone biopsy, DFO test and serum C-PTH. 19.1% of the cases had positive stainable Al and/or high bone Al content ( > 60 mg/kg/dw) and could be intoxicated. To obtain the highest sensitivity, we selected the following limit values: the lower limit of increment so far proposed for DFO test positivity ( > 150 µg/l) and a value capable of selecting patients with pathologic osteoclasia for C-PTH ( > 15 ng/ml). With these limits, four different groups of patients were recognized: group A, DFO test positive and PTH high, n = 12; group B, DFO test positive and PTH low, n = 6; group C, DFO test negative and PTH high, n = 30; group D, DFO test negative and PTH low, n = 20. In group B, which could be anticipated as being at higher risk, we actually found the highest (p < 0.05) bone Al content as compared to other groups, associated with a reduced bone formation rate. However, also in group A and D cases with high A1 content and/or positive A1 stain togheter with low bone formation rate were recorded. On the contrary, all patients in group C invariably showed low bone Al content, negative A1 stain and high-normal bone formation rates, therefore representing a category of patients not a risk of A1 toxicity. We suggest that the use of DFO test and serum C-iPTH assay, at the selected threshold levels, may be suitable to identify patients without an important Al burden, not requiring a bone biopsy to rule out the risk of A1 toxici

 

点击下载:  PDF (1535KB)



返 回